Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Mauro Magnani, Francesco Graziano et al.|British Journal of Cancer|2017Cited by 68
Prevention and Treatment of Postoperative Infections after Sinus Elevation Surgery: Clinical Consensus and RecommendationsTiziano Testori, Massimo Del Fabbro, Lorenzo Drago et al.|International Journal of Dentistry|2012Cited by 62
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal CancerFausto Petrelli, Alberto F. Sobrero, Roberto Labianca et al.|JAMA Oncology|2020Cited by 49
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Rossana Berardi, Francesco Leone et al.|European Journal of Cancer|2017Cited by 30
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Giordano Beretta, Sara Lonardi et al.|European Journal of Cancer|2021Cited by 15